Dr. Jafar Golzarian, MD

Dr. Golzarian practices at Metro Urology in Saint Paul, Minnesota.

Dr. Golzarian's NPI, 1093703944, was assigned on October 13, 2005. Dr. Golzarian graduated from Universite Libre de Bruxelles Faculty of Medicine in 1988. Dr. Golzarian holds Minnesota license 50506.

Dr. Golzarian's primary practice is Metro Urology, at 6025 Lake Rd, Saint Paul, MN 55125 in Washington County. The practice phone is (651) 999-6800.

Dr. Golzarian's primary practice is Metro Urology in Saint Paul, Minnesota. Dr. Golzarian is also affiliated with Abbott Northwestern Hospital. The medical group on file is Buffalo Hospital. Dmand AI also links Dr. Golzarian to 8 more medical groups and 6 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Golzarian practices, 7 sites in all. Vendor and product names are available with a free account.

Vascular and interventional radiology is Dr. Golzarian's primary specialty in the NPI Registry, under taxonomy code 2085R0204X. Dr. Golzarian is board certified in interventional radiology and diagnostic radiology by the American Board of Radiology. Dmand AI has Dr. Golzarian's licenses on file in 2 states: Minnesota and Iowa.

CMS data shows 3,908 Medicare services from Dr. Golzarian across 14 procedure codes in 2024, for 64 Medicare patients. Medicare paid $293,576 for them. Every service was in an office.

CMS counts 64 Medicare patients who saw Dr. Golzarian in 2024. The largest group is 65 to 74, with 30 patients. 69% of them have high blood pressure, and 67% have high cholesterol. Their average risk score is 1.01, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Golzarian's median patient age at 70, with 23% women.

In 2024, Dr. Golzarian wrote 311 Medicare Part D claims for 79 patients. 100% of them were for generic drugs. CMS names the drug for 309 of them, across 6 drugs with 11 or more claims each, at $1,264 in total drug cost. In 2023, CMS named 42 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Golzarian for performance year 2024, reported as part of a group. Dr. Golzarian accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Golzarian as offering telehealth.

Dmand AI links 145 papers to Dr. Golzarian, published from 2008 to 2025. 2020 was the busiest year, with 17. The most frequent topics are Embolization, Therapeutic, Liver Neoplasms and Carcinoma, Hepatocellular. Dr. Golzarian has published most often in J Vasc Interv Radiol. Dr. Golzarian's most frequent co-authors are Reza Talaie, MD, Siobhan Moira Flanagan, MD and Nassir Rostambeigi, MD.

Dmand AI links Dr. Golzarian to 2 clinical trials. Conditions studied include Prostatic Hyperplasia and Prostatic Diseases.

CMS Open Payments shows 457 general payments to Dr. Golzarian from 37 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 34% of the total. Boston Scientific Corporation paid the most, $262,830. It also lists 1 research payment totaling $2,250 in 2018.

Dr. Golzarian graduated from Universite Libre de Bruxelles Faculty of Medicine in 1988. Dr. Golzarian is a member of SIR.

Dr. Golzarian is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Medica. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.